Cullinan Therapeutics Inc (CGEM)
NASDAQ:CGEM
Want to see CGEM full AI Analyst Report?
Top Page
Cullinan Management
(NASDAQ:CGEM)
Select Model
Select Model
Rating:46Neutral
Price Target:
$13.00
▼(-13.68% Downside)
Action:Reiterated
Date:06/11/26
Score is held down primarily by weak financial performance (minimal revenue, increasing losses, and material cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting factors include low balance-sheet leverage and a constructive pipeline catalyst backdrop from positive early trial-data corporate events, but these do not fully counter the current fundamentals and trend.
Positive Factors
Low Leverage / Balance Sheet Strength
Very low debt reduces refinancing and interest-rate risk, giving management durable financial flexibility to fund clinical programs, pursue partnerships, or time non-dilutive financing. Over the next 2–6 months this buffer supports continued R&D and optionality without immediate solvency pressure.
Negative Factors
High Cash Burn / Large Losses
Sustained, large cash burn creates structural funding requirements and increases dilution or financing risk. Over a 2–6 month horizon the company remains dependent on external capital to sustain trials, limiting strategic flexibility and raising execution risk if capital markets tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Strength
Very low debt reduces refinancing and interest-rate risk, giving management durable financial flexibility to fund clinical programs, pursue partnerships, or time non-dilutive financing. Over the next 2–6 months this buffer supports continued R&D and optionality without immediate solvency pressure.
Read all positive factors
Cullinan Management (CGEM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$841.98M
Dividend YieldN/A
Average Volume (3M)1.16M
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue GrowthN/A
EPS Growth-19.99%
CountryUS
Employees111
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-3.75
Shares Outstanding61,458,046
10 Day Avg. Volume1,269,402
30 Day Avg. Volume1,157,780
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.87K
Enterprise Value/Ebitda-4.25
Forecast
1Y Price Target
$33.56Price Target Upside122.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.06
Revenue Forecast (FY)$19.68M
Cullinan Management Business Overview & Revenue Model
Company Description
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage...
How the Company Makes Money
Cullinan Oncology generates revenue primarily through the development, commercialization, and partnership of its oncology drug candidates. The company collaborates with research organizations, licensing its proprietary technologies and intellectua...
Cullinan Management Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.94M |
| Gross Profit | -79.00K | 0.00 | -306.00K | -310.00K | 0.00 | 18.94M |
| EBITDA | -220.72M | -219.57M | -167.15M | -190.34M | -132.04M | -67.43M |
| Net Income | -221.04M | -219.88M | -167.38M | -153.16M | 111.21M | -65.57M |
Balance Sheet | ||||||
| Total Assets | 402.98M | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M |
| Cash, Cash Equivalents and Short-Term Investments | 351.88M | 377.90M | 398.98M | 467.07M | 467.29M | 290.47M |
| Total Debt | 2.38M | 2.68M | 2.15M | 3.59M | 5.19M | 0.00 |
| Total Liabilities | 36.81M | 39.64M | 31.50M | 30.29M | 26.09M | 11.81M |
| Stockholders Equity | 366.17M | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M |
Cash Flow | ||||||
| Free Cash Flow | -178.69M | -175.80M | -145.30M | -134.48M | -127.80M | -44.02M |
| Operating Cash Flow | -178.64M | -175.75M | -145.30M | -134.28M | -126.66M | -43.43M |
| Investing Cash Flow | 175.60M | 179.99M | -136.31M | 35.81M | 248.97M | -333.77M |
| Financing Cash Flow | 1.47M | 1.09M | 266.19M | 40.75M | -25.93M | 268.78M |
Cullinan Management Technical Analysis
Neutral
15.06
Price Trends
14.48
Negative
13.94
Negative
11.29
Positive
Market Momentum
-0.40
Positive
46.05
Neutral
26.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEM, the sentiment is Neutral. The current price of 15.06 is above the 20-day moving average (MA) of 14.48, above the 50-day MA of 14.48, and above the 200-day MA of 11.29, indicating a neutral trend. The MACD of -0.40 indicates Positive momentum. The RSI at 46.05 is Neutral, neither overbought nor oversold. The STOCH value of 26.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CGEM.
Cullinan Management Risk Analysis
Cullinan Management disclosed 79 risk factors in its most recent earnings report. Cullinan Management reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cullinan Management Peers Comparison
UnderperformOutperform
Sector (51)
CGEM
Cullinan Management
13.70
4.96
56.75%
RNTX
Rein Therapeutics
0.96
-0.86
-47.42%
NEUP
Neuphoria Therapeutics
4.37
-2.33
-34.78%
Cullinan Management Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
Positive
Jun 10, 2026
On June 10, 2026, Cullinan Therapeutics reported updated Phase 1 data from its OUTRACE trials of CLN-978 in treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus, showing robust efficacy in heavily pretreate...
Business Operations and Strategy
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
Positive
Jun 8, 2026
On June 6, 2026, Cullinan Therapeutics presented initial Phase 1 data for CLN-978 in treatment-refractory systemic lupus erythematosus and rheumatoid arthritis at the EULAR Congress, based on 29 patients enrolled in the OUTRACE SLE and RA trials a...
Business Operations and StrategyProduct-Related Announcements
Cullinan Management Shares Promising Early CLN-978 Autoimmune Data
Positive
May 18, 2026
On May 18, 2026, Cullinan Therapeutics reported initial clinical data from two ongoing Phase 1 OUTRACE trials of CLN-978 in treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus. As of a January 14, 2026 cut...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.